TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04314375: Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerativ

Sponsor: Bausch Health Americas, Inc. · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$2,097,600

Rescue Site Savings

+$1,380,000

Unlock Full NCT04314375 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04314375 Rescue Dossier →